![Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation - ScienceDirect Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S036505962030115X-gr3.jpg)
Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation - ScienceDirect
![Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation - ScienceDirect Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S036505962030115X-gr4.jpg)
Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation - ScienceDirect
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional na
![Repigmentation in Vitiligo With Tofacitinib May Require Concomitant Light Exposure - Dermatology Advisor Repigmentation in Vitiligo With Tofacitinib May Require Concomitant Light Exposure - Dermatology Advisor](https://www.dermatologyadvisor.com/wp-content/uploads/sites/20/2019/01/vitiligomi01apad891_1298877.jpg)
Repigmentation in Vitiligo With Tofacitinib May Require Concomitant Light Exposure - Dermatology Advisor
![A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo - Journal of the American Academy of Dermatology A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo - Journal of the American Academy of Dermatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b25bf116-88d4-410c-b23d-61800b12b863/gr2_lrg.jpg)